ArticleFuture microbiology2011
Examining the requirements for nucleoporins by HIV-1.
Article in Future microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- A Canadian Survey of Research on HIV-1 Latency-Where Are We Now and Where Are We Heading?Viruses · 2024Review
- Article
- Article
- Viral subversion of the nuclear pore complex.Viruses · 2013Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A hallmark of HIV type 1 and other lentiviruses is their ability to infect and replicate in nondividing cells by commandeering host nuclear transport factors. During the early stages of infection, this is expected to permit the safe passage of viral preintegration complexes (PICs) through nuclear pores. Numerous nuclear transport factors have been identified as essential for HIV-1 infection by genome-wide small interfering RNA screens, and many of these are currently under investigation. Here, using knockdown studies, Matreyek and Engelman further characterize the importance of transportin-3 and nuclear pore complex component nucleoporin 153 for the early stages of HIV-1 infection and show that these two proteins operate synergistically. Also, as was previously observed for transportin-3, they show that the requirement of nucleoporin 153 for PIC nuclear entry is determined by the HIV-1 Capsid protein. The refinement of the list of key nuclear pore complex and transport proteins required for PIC entry, along with a better understanding of the specific mechanisms employed, will undoubtedly lead to the development of future antiretroviral therapies that will have the potential to block HIV-1 viral DNA integration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.